Your shopping cart is currently empty

RP-832c is a synthetic analog of a host defense peptide (HDP) that targets the mannose receptor CD206 on M2-polarized macrophages with a Kd of 3.5 μM. Upon binding to CD206, RP-832c induces significant conformational changes in the receptor, activating signaling pathways that lead to rapid apoptosis of CD206-positive M2 macrophages and their repolarization to the M1 phenotype. Treatment with RP-832c significantly reduces CD206 gene expression in M2 macrophages and temporarily increases the expression of the M1 macrophage marker TNF-α. RP-832c is applicable for research on T-cell lymphomas (CTCL) and idiopathic pulmonary fibrosis (IPF).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | RP-832c is a synthetic analog of a host defense peptide (HDP) that targets the mannose receptor CD206 on M2-polarized macrophages with a Kd of 3.5 μM. Upon binding to CD206, RP-832c induces significant conformational changes in the receptor, activating signaling pathways that lead to rapid apoptosis of CD206-positive M2 macrophages and their repolarization to the M1 phenotype. Treatment with RP-832c significantly reduces CD206 gene expression in M2 macrophages and temporarily increases the expression of the M1 macrophage marker TNF-α. RP-832c is applicable for research on T-cell lymphomas (CTCL) and idiopathic pulmonary fibrosis (IPF). |
| In vitro | RP-832c exhibits dose-dependent inhibition of M2-polarized bone marrow-derived macrophages (BMDM) within a concentration range of 0-100 μM, with an IC50 of 6.184 μM. It shows minimal cytotoxicity towards M1-polarized macrophages and no cytotoxicity to the human fetal lung fibroblast cell lines MRC5 and IMR9. At 10 μM for 24 hours, RP-832c significantly reduces CD206 expression in M2 macrophages and temporarily increases TNF-α expression. |
| In vivo | RP-832c, administered via intraperitoneal injection once daily for 10 days, inhibits tumor growth in the tumor microenvironment of cutaneous T-cell lymphoma by inducing the transition of immunosuppressive M2 macrophages to antitumor M1 macrophages. Additionally, RP-832c (5-10 mg/kg, subcutaneous injection, once daily for 21 days) demonstrates significant preventive and therapeutic effects in a mouse model of pulmonary fibrosis. |
| Molecular Weight | 1367.60 |
| Formula | C68H94N20O11 |
| Cas No. | 2375823-45-1 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.